Relaxin

also known as rhRlx · recombinant human relaxin

Developed for: congestive heart failure · atrial fibrillation · cardiovascular disorder · preeclampsia · systemic sclerosis · type 2 diabetes mellitus
Investigated by: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies · AstraZeneca · Cambridge University Hospitals NHS Foundation Trust · Deeptankar DeMazumder · McGowan Institute for Regenerative Medicine, University of Pittsburgh · MedImmune LLC
+6 more
· National Center for Research Resources (NCRR) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Relaxera Pharmaceuticals · Relaxera Pharmazeutische Gesellschaft mbH & Co. KG · Stanford University · University of Cambridge

Trials 6 · a red edge is where a trial was stopped

today NCT07359872 · Ph 1/2 NCT03449251 · Ph 2 NCT00520806 · Ph 2/3 NCT00333307 · Ph 1 NCT00259116 · Ph 2 NCT00004380 · Ph 2

199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT00333307	Oct 2006 → ?	preeclampsia	Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies	Suspended	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT07359872	Jan 2027 → Dec 2030 expected	atrial fibrillation, disorder of defective peroxisome oxidative status, heart failure, stroke disorder	Deeptankar DeMazumder	Not yet recruiting	No outcome recorded
Phase 23 trials
Phase 2	NCT03449251	Mar 2018 → Sep 2025	cardiovascular disorder, type 2 diabetes mellitus	Cambridge University Hospitals NHS Foundation Trust	Unknown	No outcome recorded
Phase 2	NCT00259116	Nov 2005 → ?	congestive heart failure	Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies	Completed	No outcome recorded
Phase 2	NCT00004380	Dec 1991 → Dec 1997	systemic sclerosis	National Center for Research Resources (NCRR)	Completed	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT00520806	Oct 2007 → Sep 2012	congestive heart failure	Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT00704665 Comparator	Dec 1998 → Dec 2001	systemic sclerosis	University of Medicine and Dentistry of New Jersey	Completed	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

Field	Value	Cited text
Known as	relaxin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00333307 ↗ 6 NCT00004380 ↗ NCT03449251 ↗ NCT07359872 ↗ NCT00520806 ↗ NCT00259116 ↗ NCT00704665 ↗
Known as	recombinant human relaxin	“A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure” NCT00259116 ↗
Known as	rhRlx	“A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure” NCT00259116 ↗ 1 “Recombinant Human Relaxin (rhRlx)” NCT00333307 ↗
Modality	Protein / enzyme biologic	“The patient is treated with subcutaneous injections of recombinant relaxin for approximately 12 months.” NCT00004380 ↗
Route	Subcutaneous	“subcutaneous injections of recombinant relaxin” NCT00004380 ↗